Skip to main content

SV Health Investors — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

76
Companies
$3.1B
Total invested
$48.4M
Avg. check
16
Industries
Biotechnology 21Health Care 15Medical 12Pharmaceutical 6Therapeutics 6Biopharma 4+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 76
Sitryx Therapeutics
September 2023

Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.

Biotechnology · Oxford$39.0M Series A
KalVista Pharmaceuticals
September 2025

KalVista Pharmaceuticals focuses on developing oral medicines, particularly for managing hereditary angioedema.

Biopharma · Cambridge$125.0M Post-IPO Debt
Spectrawave
September 2024

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices.

Biotechnology · Waltham$50.0M Series B
Alchemab Therapeutics
July 2026

Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.

Biotechnology · London$33.6M Series A
AdvanCell
July 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.

Biotechnology · Sydney$315.0M Series D
Draig Therapeutics
July 2026

Draig Therapeutics is a clinical-stage biopharmaceutical company that develops investigational therapies for neuropsychiatric disorders.

Biopharma · Cardiff$65.0M Series B
Harness Therapeutics
June 2026

Harness Therapeutics is a developer of a platform for physiological upregulation of proteins using targeted translation enhancers, SINEUPs.

Biotechnology · CambridgeGrant
Cerevance
May 2026

Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases.

Biotechnology · Boston$20.0M Series C
Transposon Therapeutics
March 2026

Transposon Therapeutics specializes in developing therapeutics for debilitating and life-threatening diseases.

Biotechnology · Westport$22.0M Grant
Rondo Therapeutics
March 2022

Rondo Therapeutics creates novel bispecific antibodies that activate the immune system to fight cancer.

Biopharma · Hayward$67.0M Series A
Mestag Therapeutics
March 2026

Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.

Biotechnology · Cambridge$40.0M Series Unknown
Dualitas Therapeutics
September 2025

Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders

Biotechnology · San Francisco$65.0M Series A
Alpheus Medical
May 2025

Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.

Biotechnology · Oakdale$52.0M Series B
Therini Bio
May 2025

Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.

Biotechnology · San Francisco$39.0M Series A
Bardy Diagnostics
May 2025

Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device .

Health Care · Seattle$10.5M Venture - Series Unknown
Imbria Pharmaceuticals
April 2025

Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.

Biotechnology · Boston$59.2M Series B
Perfuze
March 2025

Perfuze is a medical device company developing catheter-based aspiration technology to treat acute ischemic stroke.

Health Care · Newcastle$23.9M Venture - Series Unknown
Ria Health
February 2025

Ria Health is an online platform providing telehealth services for alcohol use disorder.

Health Care · San Francisco$6.5M Series B
TRex Bio
November 2024

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

Bioinformatics · South San Francisco$84.0M Series B
LOQUS23 THERAPEUTICS
October 2024

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.

Biotechnology · London$46.4M Series A
CSA Medical
September 2024

CSA Medical is a provider of innovative spray cryotherapy medical device solutions.

Biotechnology · Lutherville Timonium$53.0M Series D
U.S. Renal Care
December 2023

U.S. Renal Care is a healthcare service provider that focuses on serving patients in dialysis facilities.

Biotechnology · Plano$4.0M Venture - Series Unknown
Eyebiotech
November 2023

Eyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases.

Biotechnology · New York$65.0M Series A
X4 Pharmaceuticals
October 2025

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

Biotechnology · Cambridge$155.3M Post Ipo Equity

Where SV Health Investors invests

Biotechnology21
Health Care15
Medical12
Pharmaceutical6
Therapeutics6
Biopharma4

About SV Health Investors's portfolio

How many companies has SV Health Investors invested in?

SV Health Investors has invested in 76 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does SV Health Investors invest in?

SV Health Investors's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 16 different industry categories.

What is SV Health Investors's largest investment?

Among tracked funding rounds, AdvanCell received $315.0M in a Series D round. SV Health Investors's total known invested capital is $3.1B.

What is the average investment size for SV Health Investors?

SV Health Investors's average investment size is $48.4M across its portfolio of 76 companies.

What are SV Health Investors's most recent investments?

Recent SV Health Investors portfolio additions include Sitryx Therapeutics, KalVista Pharmaceuticals, Spectrawave, Alchemab Therapeutics, AdvanCell. These companies were founded in 2020 or later.

Reach the founders behind these 76 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →